Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Flibanserin | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | Flibanserin | hsa00040 | Pentose and glucuronate interconversions | 4.00E-02 | 1 | P15121 | AKR1B1 | More | | Flibanserin | hsa00051 | Fructose and mannose metabolism | 4.00E-02 | 2 | P60174, P04075 | TPI1, ALDOA | More | | Flibanserin | hsa00052 | Galactose metabolism | 4.27E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Flibanserin | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | | Flibanserin | hsa00220 | Arginine biosynthesis | 1.43E-02 | 2 | P05089, P49448 | ARG1, GLUD2 | More | | Flibanserin | hsa00310 | Lysine degradation | 4.57E-02 | 2 | Q96KQ7, Q02809 | EHMT2, PLOD1 | More | | Flibanserin | hsa00350 | Tyrosine metabolism | 3.40E-02 | 1 | P28332 | ADH6 | More | | Flibanserin | hsa00500 | Starch and sucrose metabolism | 1.91E-04 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Flibanserin | hsa00562 | Inositol phosphate metabolism | 2.00E-02 | 4 | P27987, P19174, P42338, Q02252 | ITPKB, PLCG1, PIK3CB, ALDH6A1 | More | | Flibanserin | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Flibanserin | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Flibanserin | hsa00630 | Glyoxylate and dicarboxylate metabolism | 1.03E-04 | 2 | P40925, P15104 | MDH1, GLUL | More | | Flibanserin | hsa00730 | Thiamine metabolism | 1.55E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Flibanserin | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | Flibanserin | hsa00790 | Folate biosynthesis | 2.02E-02 | 1 | P15121 | AKR1B1 | More | | Flibanserin | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.12E-02 | 1 | P14868 | DARS | More | | Flibanserin | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 6.26E-05 | 4 | P78417, P28332, P09211, P11712 | GSTO1, ADH6, GSTP1, CYP2C9 | More | | Flibanserin | hsa00982 | Drug metabolism - cytochrome P450 | 8.40E-04 | 3 | P11712, P78417, P28332 | CYP2C9, GSTO1, ADH6 | More | | Flibanserin | hsa00983 | Drug metabolism - other enzymes | 3.50E-02 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | | Flibanserin | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | | Flibanserin | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | Flibanserin | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | Flibanserin | hsa01240 | Biosynthesis of cofactors | 2.95E-02 | 2 | P13716, P14618 | ALAD, PKM2 | More | | Flibanserin | hsa01523 | Antifolate resistance | 1.43E-03 | 2 | Q92820, P04818 | GGH, TYMS | More | | Flibanserin | hsa01524 | Platinum drug resistance | 1.47E-03 | 3 | O15392, P11388, P31751 | BIRC5, TOP2A, AKT2 | More | | Flibanserin | hsa02010 | ABC transporters | 1.98E-03 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | | Flibanserin | hsa03010 | Ribosome | 1.13E-06 | 12 | P26373, P42677, P40429, P62917, P46776, Q9H0U6, Q07020, Q02878, P27635, P05386, P62249, P23396 | RPL13, RPS27, RPL13A, RPL8, RPL27A, MRPL18, RPL18, RPL6, RPL10, RPLP1, RPS16, RPS3 | More | | Flibanserin | hsa03013 | RNA transport | 4.21E-04 | 15 | P52298, Q09161, O14893, Q15287, Q9UBU9, Q7Z3B4, P35658, P63279, Q14152, P55884, O15371, O75822, P78345, P20042, Q9Y6A5 | NCBP2, NCBP1, GEMIN2, RNPS1, NXF1, NUP54, NUP214, UBE2I, EIF3A, EIF3B, EIF3D, EIF3J, RPP38, EIF2S2, TACC3 | More | | Flibanserin | hsa03018 | RNA degradation | 5.00E-02 | 1 | Q9NQT4 | EXOSC5 | More | | Flibanserin | hsa03020 | RNA polymerase | 5.59E-03 | 3 | P30876, P24928, P62487 | POLR2B, POLR2A, POLR2G | More | | Flibanserin | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | Flibanserin | hsa03040 | Spliceosome | 2.30E-04 | 12 | Q14562, O43143, O60508, P08579, Q15427, P38159, P61978, Q07955, Q01130, Q13243, P11142, O43447 | DHX8, DHX15, CDC40, SNRPB2, SF3B4, RBMX, HNRPK, SFRS1, SFRS2, SFRS5, HSPA8, PPIH | More | | Flibanserin | hsa03050 | Proteasome | 4.83E-02 | 1 | P55036 | PSMD4 | More | | Flibanserin | hsa03060 | Protein export | 1.20E-03 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | | Flibanserin | hsa03320 | PPAR signaling pathway | 4.33E-02 | 2 | Q6PCB7, Q9UNU6 | SLC27A1, CYP8B1 | More | | Flibanserin | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | | Flibanserin | hsa04012 | ErbB signaling pathway | 1.11E-03 | 8 | P21860, Q13153, P16333, P17252, Q13557, P19174, O14944, P42338 | ERBB3, PAK1, NCK1, PRKCA, CAMK2D, PLCG1, EREG, PIK3CB | More | | Flibanserin | hsa04014 | Ras signaling pathway | 1.48E-04 | 11 | P31751, P42338, P20827, P49767, Q13009, P17252, P14921, P0DP23, P62873, P50151, P19174 | AKT2, PIK3CB, EFNA1, VEGFC, TIAM1, PRKCA, ETS1, CALM1, GNB1, GNG10, PLCG1 | More | | Flibanserin | hsa04015 | Rap1 signaling pathway | 1.52E-03 | 9 | P20827, P49767, P11215, Q13009, P42338, P31751, P0DP23, P17252, P19174 | EFNA1, VEGFC, ITGAM, TIAM1, PIK3CB, AKT2, CALM1, PRKCA, PLCG1 | More | | Flibanserin | hsa04020 | Calcium signaling pathway | 2.34E-04 | 12 | P27987, Q96DU7, P45880, Q13557, P17252, P21860, O15399, P19174, P0DP23, P51828, P23634, P49767 | ITPKB, ITPKC, VDAC2, CAMK2D, PRKCA, ERBB3, GRIN2D, PLCG1, CALM1, ADCY7, ATP2B4, VEGFC | More | | Flibanserin | hsa04022 | cGMP-PKG signaling pathway | 3.48E-03 | 6 | Q99941, P23634, P31751, P51828, P45880, P0DP23 | CREBL1, ATP2B4, AKT2, ADCY7, VDAC2, CALM1 | More | | Flibanserin | hsa04024 | cAMP signaling pathway | 1.17E-03 | 8 | P42338, P31751, P0DP23, Q13370, O15399, P25963, Q13009, Q13153 | PIK3CB, AKT2, CALM1, PDE3B, GRIN2D, NFKBIA, TIAM1, PAK1 | More | | Flibanserin | hsa04062 | Chemokine signaling pathway | 1.25E-02 | 9 | P42338, P19174, P62873, P50151, P43250, Q13009, P14598, P42224, P25963 | PIK3CB, PLCG1, GNB1, GNG10, GRK6, TIAM1, NCF1, STAT1, NFKBIA | More | | Flibanserin | hsa04064 | NF-kappa B signaling pathway | 8.89E-09 | 21 | P10415, Q13489, P25963, P51617, O00463, Q13546, P14778, P01584, P01375, Q04759, Q9UDY8, Q13077, Q16548, Q8WV28, Q13315, P63279, P24522, Q8NHW4, P09341, Q9UNE0, Q9NQC7 | BCL2, BIRC3, NFKBIA, IRAK1, TRAF5, RIPK1, IL1R1, IL1B, TNF, PRKCQ, MALT1, TRAF1, BCL2A1, BLNK, ATM, UBE2I, GADD45A, CCL4L2, CXCL1, EDAR, CYLD | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P05164 | MPO | Myeloperoxidase | P10415 | BCL2 | Apoptosis regulator Bcl-2 | -0.81 | P08246 | ELA2 | Neutrophil elastase | P10415 | BCL2 | Apoptosis regulator Bcl-2 | -0.942 | P08235 | NR3C2 | Mineralocorticoid receptor | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | 0.868 | P08246 | ELA2 | Neutrophil elastase | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.716 | P08246 | ELA2 | Neutrophil elastase | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.701 | P08246 | ELA2 | Neutrophil elastase | P51617 | IRAK1 | Interleukin-1 receptor-associated kinase 1 | -0.734 | P05164 | MPO | Myeloperoxidase | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.821 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.837 | P08246 | ELA2 | Neutrophil elastase | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.814 | P08235 | NR3C2 | Mineralocorticoid receptor | Q13546 | RIPK1 | Receptor-interacting serine/threonine-protein kinase 1 | -0.749 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.76 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P01584 | IL1B | Interleukin-1 beta | 0.799 | P08246 | ELA2 | Neutrophil elastase | P01375 | TNF | Tumor necrosis factor | 0.751 | P05164 | MPO | Myeloperoxidase | Q04759 | PRKCQ | Protein kinase C theta type | -0.88 | P08246 | ELA2 | Neutrophil elastase | Q04759 | PRKCQ | Protein kinase C theta type | -0.748 | P08235 | NR3C2 | Mineralocorticoid receptor | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | 0.708 | P05164 | MPO | Myeloperoxidase | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | -0.758 | P08246 | ELA2 | Neutrophil elastase | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | -0.896 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.73 | P08246 | ELA2 | Neutrophil elastase | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.725 | P05164 | MPO | Myeloperoxidase | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.782 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.875 | P08246 | ELA2 | Neutrophil elastase | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.766 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q8WV28 | BLNK | B-cell linker protein | -0.816 | P05164 | MPO | Myeloperoxidase | Q13315 | ATM | Serine-protein kinase ATM | -0.725 | P08246 | ELA2 | Neutrophil elastase | Q13315 | ATM | Serine-protein kinase ATM | -0.742 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P63279 | UBE2I | SUMO-conjugating enzyme UBC9 | 0.756 | P05164 | MPO | Myeloperoxidase | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.812 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.796 | P08246 | ELA2 | Neutrophil elastase | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.7 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.802 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.802 | P05164 | MPO | Myeloperoxidase | P09341 | CXCL1 | Growth-regulated alpha protein | 0.806 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P09341 | CXCL1 | Growth-regulated alpha protein | 0.7 | P08235 | NR3C2 | Mineralocorticoid receptor | Q9UNE0 | EDAR | Tumor necrosis factor receptor superfamily member EDAR | 0.819 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q9NQC7 | CYLD | Ubiquitin carboxyl-terminal hydrolase CYLD | 0.825 |
| Flibanserin | hsa04070 | Phosphatidylinositol signaling system | 2.95E-04 | 8 | P19174, P0DP23, P42338, P23743, Q86XP1, P27987, Q96DU7, P17252 | PLCG1, CALM1, PIK3CB, DGKA, DGKH, ITPKB, ITPKC, PRKCA | More | | Flibanserin | hsa04071 | Sphingolipid signaling pathway | 3.82E-05 | 7 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, P10415 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, BCL2 | More | | Flibanserin | hsa04080 | Neuroactive ligand-receptor interaction | 8.77E-05 | 10 | P08311, P28472, Q15722, P21453, Q9H228, O00398, P21462, P21730, Q16581, P07550 | CTSG, GABRB3, LTB4R, S1PR1, EDG8, P2RY10, FPR1, C5AR1, C3AR1, ADRB2 | More | | Flibanserin | hsa04110 | Cell cycle | 1.97E-05 | 7 | P06493, O60566, O75293, P30304, P33981, P42773, P01106 | CDK1, BUB1B, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | | Flibanserin | hsa04114 | Oocyte meiosis | 2.21E-04 | 5 | Q9Y6D9, P51812, Q02750, P16298, Q17RY0 | MAD1L1, RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | Flibanserin | hsa04115 | p53 signaling pathway | 3.32E-03 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | | Flibanserin | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Flibanserin | hsa04141 | Protein processing in endoplasmic reticulum | 3.64E-02 | 5 | Q99941, O75460, P11142, Q9H3Z4, P07900 | CREBL1, ERN1, HSPA8, DNAJC5, HSP90AA1 | More | | Flibanserin | hsa04142 | Lysosome | 1.46E-02 | 7 | P06865, P22304, P38571, Q13510, P07602, Q9NRA2, P61916 | HEXA, IDS, LIPA, ASAH1, PSAP, SLC17A5, NPC2 | More | | Flibanserin | hsa04144 | Endocytosis | 1.67E-02 | 8 | P0DMV8, Q9H444, O75351, P62491, Q96B97, Q15438, Q14161, Q9UMY4 | HSPA1A, CHMP4B, VPS4B, RAB11A, SH3KBP1, PSCD1, GIT2, SNX12 | More | | Flibanserin | hsa04145 | Phagosome | 1.98E-02 | 8 | Q15080, P14598, Q13509, Q13488, P05164, O60603, P35443, P13765 | NCF4, NCF1, TUBB3, TCIRG1, MPO, TLR2, THBS4, HLA-DOB | More | | Flibanserin | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | | Flibanserin | hsa04151 | PI3K-Akt signaling pathway | 1.43E-02 | 12 | P42338, P20827, P49767, P08238, P62873, P50151, P16144, O15335, Q13751, P14784, P01568, P17252 | PIK3CB, EFNA1, VEGFC, HSP90AB1, GNB1, GNG10, ITGB4, CHAD, LAMB3, IL2RB, IFNA21, PRKCA | More | | Flibanserin | hsa04210 | Apoptosis | 1.53E-03 | 12 | Q13315, P10415, Q13489, O76075, P25963, P01375, P24522, Q16548, Q13077, P43234, P18848, Q14643 | ATM, BCL2, BIRC3, DFFB, NFKBIA, TNF, GADD45A, BCL2A1, TRAF1, CTSO, ATF4, ITPR1 | More | | Flibanserin | hsa04211 | Longevity regulating pathway | 1.18E-02 | 3 | Q12778, Q9UEF7, Q96KQ7 | FOXO1, KL, EHMT2 | More | | Flibanserin | hsa04213 | Longevity regulating pathway - multiple species | 2.82E-02 | 3 | Q08828, P51828, P0DMV8 | ADCY1, ADCY7, HSPA1A | More | | Flibanserin | hsa04217 | Necroptosis | 3.61E-04 | 12 | P01375, P01568, P48023, Q13489, Q13546, P42224, Q14765, P08238, P15104, Q6FI13, Q99878, O43633 | TNF, IFNA21, FASLG, BIRC3, RIPK1, STAT1, STAT4, HSP90AB1, GLUL, H2AC18; H2AC19, H2AC14, CHMP2A | More | | Flibanserin | hsa04218 | Cellular senescence | 1.92E-04 | 10 | P01106, P31751, P30281, O75293, P30304, P06493, P0DP23, P01889, P10321, P12236 | MYC, AKT2, CCND3, GADD45B, CDC25A, CDK1, CALM1, HLA-B, HLA-C, SLC25A6 | More | | Flibanserin | hsa04261 | Adrenergic signaling in cardiomyocytes | 3.21E-04 | 10 | P07550, P51828, P22694, P31751, Q99941, P18848, Q13362, P0DP23, Q13557, P23634 | ADRB2, ADCY7, PRKACB, AKT2, CREBL1, ATF4, PPP2R5C, CALM1, CAMK2D, ATP2B4 | More | | Flibanserin | hsa04270 | Vascular smooth muscle contraction | 6.96E-03 | 6 | P0DP23, Q08828, P51828, P35579, P35749, P35318 | CALM1, ADCY1, ADCY7, MYH9, MYH11, ADM | More | | Flibanserin | hsa04330 | Notch signaling pathway | 4.34E-02 | 2 | Q92542, P46531 | NCSTN, NOTCH1 | More | | Flibanserin | hsa04360 | Axon guidance | 2.13E-03 | 7 | P16333, P20827, O95631, P17252, P42338, P23528, P19174 | NCK1, EFNA1, NTN1, PRKCA, PIK3CB, CFL1, PLCG1 | More | | Flibanserin | hsa04370 | VEGF signaling pathway | 3.18E-07 | 7 | P19174, P16298, P31751, P42338, P17252, Q05397, Q02750 | PLCG1, PPP3CB, AKT2, PIK3CB, PRKCA, PTK2, MAP2K1 | More | | Flibanserin | hsa04371 | Apelin signaling pathway | 3.23E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | | Flibanserin | hsa04380 | Osteoclast differentiation | 2.72E-04 | 8 | Q9NQC7, Q9UQC2, Q16539, P31751, P14778, O75015, P01375, Q8N149 | CYLD, GAB2, MAPK14, AKT2, IL1R1, FCGR3B, TNF, LILRA2 | More | | Flibanserin | hsa04392 | Hippo signaling pathway - multiple species | 1.51E-02 | 1 | Q13153 | PAK1 | More | | Flibanserin | hsa04510 | Focal adhesion | 7.77E-03 | 9 | P16144, O75369, P42338, Q15942, P17252, O15335, Q13751, Q13489, P49767 | ITGB4, FLNB, PIK3CB, ZYX, PRKCA, CHAD, LAMB3, BIRC3, VEGFC | More | | Flibanserin | hsa04512 | ECM-receptor interaction | 1.90E-02 | 2 | P26012, P16070 | ITGB8, CD44 | More | | Flibanserin | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | Flibanserin | hsa04610 | Complement and coagulation cascades | 1.91E-03 | 1 | P0C0L4 | C4A | More | | Flibanserin | hsa04612 | Antigen processing and presentation | 5.99E-06 | 9 | P13765, P48382, Q14953, P26715, P26717, Q07444, Q13241, P01732, P01375 | HLA-DOB, RFX5, KIR2DS5, KLRC1, KLRC2, KLRC3, KLRD1, CD8A, TNF | More | | Flibanserin | hsa04613 | Neutrophil extracellular trap formation | 2.55E-05 | 20 | P17252, O60603, P05164, P08246, Q9UM07, P04908, Q6FI13, Q93077, P62807, O60814, P68431, P14598, Q15080, P20160, P08311, P49913, P21730, P21462, O43315, Q16539 | PRKCA, TLR2, MPO, ELA2, PADI4, H2AC4; H2AC8, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, AZU1, CTSG, CAMP, C5AR1, FPR1, AQP9, MAPK14 | More | | Flibanserin | hsa04620 | Toll-like receptor signaling pathway | 4.81E-03 | 3 | Q13546, P01568, P31751 | RIPK1, IFNA21, AKT2 | More | | Flibanserin | hsa04621 | NOD-like receptor signaling pathway | 7.18E-04 | 13 | Q14643, P01568, P25963, Q13489, Q9H1Y0, P43490, O00463, P10415, Q13546, Q05823, P01375, P49913, P12838 | ITPR1, IFNA21, NFKBIA, BIRC3, ATG5, PBEF1, TRAF5, BCL2, RIPK1, RNASEL, TNF, CAMP, DEFA4 | More | | Flibanserin | hsa04622 | RIG-I-like receptor signaling pathway | 1.02E-03 | 3 | P01568, Q9NQC7, Q13546 | IFNA21, CYLD, RIPK1 | More | | Flibanserin | hsa04623 | Cytosolic DNA-sensing pathway | 1.32E-05 | 5 | P01584, P01568, Q13546, P25963, Q8NHW4 | IL1B, IFNA21, RIPK1, NFKBIA, CCL4L2 | More | | Flibanserin | hsa04625 | C-type lectin receptor signaling pathway | 3.64E-05 | 8 | Q9ULY5, Q13153, Q9NQC7, P20749, P01375, P31751, P0DP23, Q16539 | CLEC4E, PAK1, CYLD, BCL3, TNF, AKT2, CALM1, MAPK14 | More | | Flibanserin | hsa04640 | Hematopoietic cell lineage | 4.71E-03 | 5 | P21926, P07766, P01730, P06127, P09564 | CD9, CD3E, CD4, CD5, CD7 | More | | Flibanserin | hsa04650 | Natural killer cell mediated cytotoxicity | 1.90E-10 | 14 | P16298, P50591, P01375, P06239, P20963, Q02750, Q13153, Q13241, P26718, O14931, P26717, Q07444, Q14953, P26715 | PPP3CB, TNFSF10, TNF, LCK, CD247, MAP2K1, PAK1, KLRD1, KLRK1, NCR3, KLRC2, KLRC3, KIR2DS5, KLRC1 | More | | Flibanserin | hsa04657 | IL-17 signaling pathway | 1.46E-04 | 8 | O00463, Q16539, P49841, P09341, P19875, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, LCN2, TNF | More | | Flibanserin | hsa04658 | Th1 and Th2 cell differentiation | 7.09E-05 | 7 | Q04759, P20963, P09693, P06239, P23771, Q9UL17, Q13761 | PRKCQ, CD247, CD3G, LCK, GATA3, TBX21, RUNX3 | More | | Flibanserin | hsa04659 | Th17 cell differentiation | 5.26E-04 | 12 | P25963, Q04759, P19174, P06239, P42224, P14784, P40189, Q9UL17, P23771, P08238, P09693, P20963 | NFKBIA, PRKCQ, PLCG1, LCK, STAT1, IL2RB, IL6ST, TBX21, GATA3, HSP90AB1, CD3G, CD247 | More | | Flibanserin | hsa04660 | T cell receptor signaling pathway | 4.59E-05 | 12 | P01375, P25963, Q9UDY8, Q04759, P10747, O95267, Q08881, Q13153, P20963, P09693, P01732, P06239 | TNF, NFKBIA, MALT1, PRKCQ, CD28, RASGRP1, ITK, PAK1, CD247, CD3G, CD8A, LCK | More | | Flibanserin | hsa04662 | B cell receptor signaling pathway | 1.60E-04 | 6 | P31751, P42338, P60033, P07948, P21854, Q8N149 | AKT2, PIK3CB, CD81, LYN, CD72, LILRA2 | More | | Flibanserin | hsa04664 | Fc epsilon RI signaling pathway | 3.91E-05 | 9 | P01375, P31751, Q16539, P42338, P17252, Q9UQC2, P07948, P19174, P09917 | TNF, AKT2, MAPK14, PIK3CB, PRKCA, GAB2, LYN, PLCG1, ALOX5 | More | | Flibanserin | hsa04666 | Fc gamma R-mediated phagocytosis | 8.08E-03 | 5 | P42338, P19174, P23528, P14598, P17252 | PIK3CB, PLCG1, CFL1, NCF1, PRKCA | More | | Flibanserin | hsa04668 | TNF signaling pathway | 2.91E-05 | 13 | P01375, O00463, Q13489, Q16539, P25963, Q99941, P18848, P19875, P01584, P20749, Q13077, P14780, O95429 | TNF, TRAF5, BIRC3, MAPK14, NFKBIA, CREBL1, ATF4, CXCL2, IL1B, BCL3, TRAF1, MMP9, BAG4 | More | | Flibanserin | hsa04670 | Leukocyte transendothelial migration | 4.20E-02 | 7 | P14780, Q96A32, P17252, P14598, Q15080, Q08881, P42681 | MMP9, MYLPF, PRKCA, NCF1, NCF4, ITK, TXK | More | | Flibanserin | hsa04713 | Circadian entrainment | 1.24E-02 | 5 | O15399, P0DP23, P17252, P62873, P50151 | GRIN2D, CALM1, PRKCA, GNB1, GNG10 | More | | Flibanserin | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | Flibanserin | hsa04720 | Long-term potentiation | 9.52E-04 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | | Flibanserin | hsa04722 | Neurotrophin signaling pathway | 1.26E-03 | 5 | P31751, P49841, O43524, P48023, P0DP23 | AKT2, GSK3B, FOXO3, FASLG, CALM1 | More | | Flibanserin | hsa04724 | Glutamatergic synapse | 1.44E-04 | 6 | O15399, P17252, P62873, P63218, P50151, P15104 | GRIN2D, PRKCA, GNB1, GNG5, GNG10, GLUL | More | | Flibanserin | hsa04725 | Cholinergic synapse | 6.02E-04 | 9 | P22694, Q14643, P17252, P62873, P63218, P50151, P18848, P42338, P10415 | PRKACB, ITPR1, PRKCA, GNB1, GNG5, GNG10, ATF4, PIK3CB, BCL2 | More | | Flibanserin | hsa04726 | Serotonergic synapse | 2.54E-02 | 5 | P17252, P62873, P50151, P33260, P09917 | PRKCA, GNB1, GNG10, CYP2C18, ALOX5 | More | | Flibanserin | hsa04727 | GABAergic synapse | 5.11E-04 | 5 | P62873, P63218, P50151, P15104, P17252 | GNB1, GNG5, GNG10, GLUL, PRKCA | More | | Flibanserin | hsa04728 | Dopaminergic synapse | 3.23E-03 | 2 | P31751, P0DP23 | AKT2, CALM1 | More | | Flibanserin | hsa04740 | Olfactory transduction | 9.46E-04 | 2 | Q9H255, P0DP23 | OR51E2, CALM1 | More | | Flibanserin | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | Flibanserin | hsa04744 | Phototransduction | 3.44E-03 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Flibanserin | hsa04750 | Inflammatory mediator regulation of TRP channels | 3.89E-03 | 5 | P01584, Q08828, P51828, Q13557, P0DP23 | IL1B, ADCY1, ADCY7, CAMK2D, CALM1 | More | | Flibanserin | hsa04910 | Insulin signaling pathway | 9.82E-04 | 2 | P0DP23, P31751 | CALM1, AKT2 | More | | Flibanserin | hsa04911 | Insulin secretion | 1.48E-02 | 3 | P51828, Q99941, Q13557 | ADCY7, CREBL1, CAMK2D | More | | Flibanserin | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | Flibanserin | hsa04914 | Progesterone-mediated oocyte maturation | 5.49E-05 | 9 | Q17RY0, P42338, Q13370, Q9UJX4, Q9Y6D9, P30304, P08238, P51812, Q02750 | CPEB4, PIK3CB, PDE3B, ANAPC5, MAD1L1, CDC25A, HSP90AB1, RPS6KA3, MAP2K1 | More | | Flibanserin | hsa04915 | Estrogen signaling pathway | 1.36E-04 | 14 | P14780, P22694, Q99941, P18848, Q08828, P51828, P31751, P07900, P0DMV8, P11142, Q14643, P0DP23, Q15788, P10415 | MMP9, PRKACB, CREBL1, ATF4, ADCY1, ADCY7, AKT2, HSP90AA1, HSPA1A, HSPA8, ITPR1, CALM1, NCOA1, BCL2 | More | | Flibanserin | hsa04916 | Melanogenesis | 4.78E-02 | 1 | P0DP23 | CALM1 | More | | Flibanserin | hsa04917 | Prolactin signaling pathway | 2.41E-02 | 1 | P31751 | AKT2 | More | | Flibanserin | hsa04918 | Thyroid hormone synthesis | 3.50E-02 | 3 | P22694, P18848, Q14643 | PRKACB, ATF4, ITPR1 | More | | Flibanserin | hsa04920 | Adipocytokine signaling pathway | 1.22E-02 | 5 | P25963, P33121, Q04759, P31751, P01375 | NFKBIA, ACSL1, PRKCQ, AKT2, TNF | More | | Flibanserin | hsa04922 | Glucagon signaling pathway | 4.86E-04 | 4 | P14618, P06737, P31751, P0DP23 | PKM2, PYGL, AKT2, CALM1 | More | | Flibanserin | hsa04923 | Regulation of lipolysis in adipocytes | 3.01E-02 | 1 | P31751 | AKT2 | More | | Flibanserin | hsa04924 | Renin secretion | 6.02E-03 | 3 | P22694, P07550, P0DP23 | PRKACB, ADRB2, CALM1 | More | | Flibanserin | hsa04925 | Aldosterone synthesis and secretion | 5.19E-03 | 4 | Q99941, P51828, Q13557, P23634 | CREBL1, ADCY7, CAMK2D, ATP2B4 | More | | Flibanserin | hsa04926 | Relaxin signaling pathway | 2.34E-05 | 12 | P25963, P42338, P62873, P63218, P50151, P18848, P22694, P49767, P14780, P17252, P30679, P49407 | NFKBIA, PIK3CB, GNB1, GNG5, GNG10, ATF4, PRKACB, VEGFC, MMP9, PRKCA, GNA15, ARRB1 | More | | Flibanserin | hsa04927 | Cortisol synthesis and secretion | 4.44E-04 | 3 | Q14643, P18848, P22694 | ITPR1, ATF4, PRKACB | More | | Flibanserin | hsa04928 | Parathyroid hormone synthesis, secretion and action | 2.13E-02 | 5 | Q14643, P22694, P23771, P18848, P10415 | ITPR1, PRKACB, GATA3, ATF4, BCL2 | More | | Flibanserin | hsa04929 | GnRH secretion | 3.61E-03 | 3 | P42338, P31751, P49407 | PIK3CB, AKT2, ARRB1 | More | | Flibanserin | hsa04932 | Non-alcoholic fatty liver disease | 7.01E-05 | 11 | P01375, P49841, O43521, P48023, O75460, P01584, P13073, P12074, Q16718, O95298, O14521 | TNF, GSK3B, BCL2L11, FASLG, ERN1, IL1B, COX4I1, COX6A1, NDUFA5, NDUFC2, SDHD | More | | Flibanserin | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.43E-02 | 5 | P42224, P42338, P49767, P17252, P19174 | STAT1, PIK3CB, VEGFC, PRKCA, PLCG1 | More | | Flibanserin | hsa04934 | Cushing syndrome | 3.48E-03 | 4 | Q99941, P51828, O15169, Q13557 | CREBL1, ADCY7, AXIN1, CAMK2D | More | | Flibanserin | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Flibanserin | hsa04964 | Proximal tubule bicarbonate reclamation | 4.48E-02 | 1 | P00918 | CA2 | More | | Flibanserin | hsa04966 | Collecting duct acid secretion | 4.48E-02 | 1 | P00918 | CA2 | More | | Flibanserin | hsa04970 | Salivary secretion | 9.54E-05 | 8 | P07550, Q08828, P51828, P22694, Q14643, P17252, P0DP23, P49913 | ADRB2, ADCY1, ADCY7, PRKACB, ITPR1, PRKCA, CALM1, CAMP | More | | Flibanserin | hsa04971 | Gastric acid secretion | 2.57E-03 | 4 | P51828, P15311, P0DP23, Q13557 | ADCY7, VIL2, CALM1, CAMK2D | More | | Flibanserin | hsa04973 | Carbohydrate digestion and absorption | 2.41E-02 | 1 | P31751 | AKT2 | More | | Flibanserin | hsa04975 | Fat digestion and absorption | 2.80E-02 | 1 | O14494 | PLPP1 | More | | Flibanserin | hsa04976 | Bile secretion | 3.14E-03 | 5 | O43315, Q08828, P51828, P08183, Q14032 | AQP9, ADCY1, ADCY7, ABCB1, BAAT | More | | Flibanserin | hsa05010 | Alzheimer disease | 7.84E-04 | 10 | Q92542, P05496, P12074, Q00535, O75460, P0DP23, P01584, O15169, P31751, P45880 | NCSTN, ATP5G1, COX6A1, CDK5, ERN1, CALM1, IL1B, AXIN1, AKT2, VDAC2 | More | | Flibanserin | hsa05016 | Huntington disease | 2.46E-02 | 9 | O95298, P13073, P12074, P24928, P30876, P62487, O75460, P28070, O00232 | NDUFC2, COX4I1, COX6A1, POLR2A, POLR2B, POLR2G, ERN1, PSMB4, PSMD12 | More | | Flibanserin | hsa05020 | Prion disease | 1.01E-04 | 13 | P01584, P46531, P11142, Q16718, O14521, P05496, P12074, Q92736, P45880, O60282, P49841, Q99941, Q16539 | IL1B, NOTCH1, HSPA8, NDUFA5, SDHD, ATP5G1, COX6A1, RYR2, VDAC2, KIF5C, GSK3B, CREBL1, MAPK14 | More | | Flibanserin | hsa05022 | Pathways of neurodegeneration - multiple diseases | 4.25E-03 | 8 | P49841, Q16718, O14521, Q13561, Q16539, Q00535, Q08752, P0DP23 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, CDK5, PPID, CALM1 | More | | Flibanserin | hsa05030 | Cocaine addiction | 4.19E-02 | 1 | Q00535 | CDK5 | More | | Flibanserin | hsa05031 | Amphetamine addiction | 6.98E-03 | 4 | P0DP23, P22694, P18848, Q13547 | CALM1, PRKACB, ATF4, HDAC1 | More | | Flibanserin | hsa05032 | Morphine addiction | 1.24E-02 | 5 | P62873, P50151, Q13370, P17252, P43250 | GNB1, GNG10, PDE3B, PRKCA, GRK6 | More | | Flibanserin | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Flibanserin | hsa05110 | Vibrio cholerae infection | 3.15E-02 | 3 | Q13488, P17252, P19174 | TCIRG1, PRKCA, PLCG1 | More | | Flibanserin | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.10E-03 | 5 | Q16539, Q13153, P09341, P25024, P25025 | MAPK14, PAK1, CXCL1, CXCR1, CXCR2 | More | | Flibanserin | hsa05131 | Shigellosis | 3.34E-02 | 11 | P01375, P25963, O00463, Q04759, Q9UDY8, Q9H1Y0, Q14643, Q12778, Q13315, P10415, Q96A32 | TNF, NFKBIA, TRAF5, PRKCQ, MALT1, ATG5, ITPR1, FOXO1, ATM, BCL2, MYLPF | More | | Flibanserin | hsa05132 | Salmonella infection | 4.28E-04 | 15 | P51617, P25963, P01375, Q9UJU2, O00471, Q13546, Q13489, P10415, Q96A32, O60603, Q9BQS8, Q13561, O60282, Q13509, P68371 | IRAK1, NFKBIA, TNF, LEF1, EXOC5, RIPK1, BIRC3, BCL2, MYLPF, TLR2, FYCO1, DCTN2, KIF5C, TUBB3, TUBB2C | More | | Flibanserin | hsa05133 | Pertussis | 3.51E-02 | 1 | P0C0L4 | C4A | More | | Flibanserin | hsa05134 | Legionellosis | 2.82E-02 | 3 | P01584, Q9NR31, P0DMV8 | IL1B, SAR1A, HSPA1A | More | | Flibanserin | hsa05135 | Yersinia infection | 3.29E-02 | 4 | Q05397, P51812, Q02750, Q96JJ3 | PTK2, RPS6KA3, MAP2K1, ELMO2 | More | | Flibanserin | hsa05140 | Leishmaniasis | 9.33E-04 | 10 | O75015, P14598, P13765, O60603, P25963, P01375, P49006, Q16539, P51617, Q15080 | FCGR3B, NCF1, HLA-DOB, TLR2, NFKBIA, TNF, MARCKSL1, MAPK14, IRAK1, NCF4 | More | | Flibanserin | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | Flibanserin | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | | Flibanserin | hsa05145 | Toxoplasmosis | 2.98E-03 | 11 | P51617, P25963, P01375, P10415, Q13489, P42224, P13765, P09917, Q13751, P11142, O60603 | IRAK1, NFKBIA, TNF, BCL2, BIRC3, STAT1, HLA-DOB, ALOX5, LAMB3, HSPA8, TLR2 | More | | Flibanserin | hsa05146 | Amoebiasis | 2.80E-04 | 11 | P09341, P19875, P14778, P27930, P01375, O60603, P05089, P30679, P22694, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, ARG1, GNA15, PRKACB, ACTN1, CTSG | More | | Flibanserin | hsa05150 | Staphylococcus aureus infection | 1.31E-02 | 2 | P0C0L4, P13646 | C4A, KRT13 | More | | Flibanserin | hsa05152 | Tuberculosis | 7.36E-03 | 11 | Q13488, P0DP23, P48382, O60603, P01375, P31751, P10415, P13765, P49913, Q9UDY8, P51617 | TCIRG1, CALM1, RFX5, TLR2, TNF, AKT2, BCL2, HLA-DOB, CAMP, MALT1, IRAK1 | More | | Flibanserin | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Flibanserin | hsa05161 | Hepatitis B | 2.33E-02 | 8 | P17252, P14780, P25963, P01375, P10415, P51617, O60603, Q14765 | PRKCA, MMP9, NFKBIA, TNF, BCL2, IRAK1, TLR2, STAT4 | More | | Flibanserin | hsa05162 | Measles | 3.18E-02 | 4 | P23458, P0DMV8, P01584, Q9NP90 | JAK1, HSPA1A, IL1B, RAB9B | More | | Flibanserin | hsa05163 | Human cytomegalovirus infection | 1.00E-05 | 23 | P31751, P42338, P01375, P25963, P62873, P50151, Q14643, P0DP23, Q8NHW4, Q08828, P51828, P23458, P49841, P14778, P01584, P17252, Q13651, P25025, Q16539, P04637, O00463, P30101, P01568 | AKT2, PIK3CB, TNF, NFKBIA, GNB1, GNG10, ITPR1, CALM1, CCL4L2, ADCY1, ADCY7, JAK1, GSK3B, IL1R1, IL1B, PRKCA, IL10RA, CXCR2, MAPK14, TP53, TRAF5, PDIA3, IFNA21 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P31751 | AKT2 | RAC-beta serine/threonine-protein kinase | P31751 | AKT2 | RAC-beta serine/threonine-protein kinase | 1 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.743 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P01375 | TNF | Tumor necrosis factor | 0.732 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.73 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | 0.837 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.712 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q14643 | ITPR1 | Inositol 1,4,5-trisphosphate receptor type 1 | -0.728 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P0DP23 | CALM1 | Calmodulin-1 | 0.926 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P0DP23 | CALM1 | Calmodulin-1 | 0.822 | P31751 | AKT2 | RAC-beta serine/threonine-protein kinase | P0DP23 | CALM1 | Calmodulin-1 | 0.761 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.802 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.802 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q08828 | ADCY1 | Adenylate cyclase type 1 | 0.84 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P51828 | ADCY7 | Adenylate cyclase type 7 | 0.834 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.78 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.76 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.778 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P01584 | IL1B | Interleukin-1 beta | 0.799 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P17252 | PRKCA | Protein kinase C alpha type | -0.725 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q13651 | IL10RA | Interleukin-10 receptor subunit alpha | 0.799 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.889 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.861 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.78 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P04637 | TP53 | Cellular tumor antigen p53 | -0.823 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.837 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.734 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P30101 | PDIA3 | Protein disulfide-isomerase A3 | 0.739 | O95271 | TNKS | Poly [ADP-ribose] polymerase tankyrase-1 | P01568 | IFNA21 | Interferon alpha-21 | -0.868 |
| Flibanserin | hsa05165 | Human papillomavirus infection | 2.26E-02 | 6 | Q16363, P30281, Q9UM47, P01889, P10321, Q99437 | LAMA4, CCND3, NOTCH3, HLA-B, HLA-C, ATP6V0B | More | | Flibanserin | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 2.73E-06 | 14 | P01568, P31751, P42224, P25963, P42338, P40189, P62873, P62879, P50151, P19174, P16298, Q02750, P0DP23, P0CG47 | IFNA21, AKT2, STAT1, NFKBIA, PIK3CB, IL6ST, GNB1, GNB2, GNG10, PLCG1, PPP3CB, MAP2K1, CALM1, UBB | More | | Flibanserin | hsa05168 | Herpes simplex virus 1 infection | 6.31E-03 | 13 | P25963, P01568, P42224, Q07955, Q01130, Q13243, Q13489, P30101, P42338, Q13398, Q03923, O75820, Q9UDV6 | NFKBIA, IFNA21, STAT1, SFRS1, SFRS2, SFRS5, BIRC3, PDIA3, PIK3CB, ZNF211, ZNF85, ZNF189, ZNF212 | More | | Flibanserin | hsa05169 | Epstein-Barr virus infection | 3.72E-02 | 6 | Q13547, P42338, P07948, Q13761, O75293, P07766 | HDAC1, PIK3CB, LYN, RUNX3, GADD45B, CD3E | More | | Flibanserin | hsa05170 | Human immunodeficiency virus 1 infection | 6.52E-08 | 27 | P31751, P42338, Q02750, P62873, P62879, P50151, P16298, P0DP23, P01375, Q05397, P17252, O00463, P30101, Q14643, P01568, P51617, P25963, O60603, Q13315, O95067, P19174, P23528, P10415, Q13619, Q93034, Q9Y6Q5, P20333 | AKT2, PIK3CB, MAP2K1, GNB1, GNB2, GNG10, PPP3CB, CALM1, TNF, PTK2, PRKCA, TRAF5, PDIA3, ITPR1, IFNA21, IRAK1, NFKBIA, TLR2, ATM, CCNB2, PLCG1, CFL1, BCL2, CUL4A, CUL5, AP1M2, TNFRSF1B | More | | Flibanserin | hsa05171 | Coronavirus disease - COVID-19 | 1.86E-04 | 18 | P25963, P42224, P01568, P23396, P62249, P42677, P40429, Q02878, P62917, P27635, P26373, Q07020, P46776, P05386, P40189, P42338, P19174, P17252 | NFKBIA, STAT1, IFNA21, RPS3, RPS16, RPS27, RPL13A, RPL6, RPL8, RPL10, RPL13, RPL18, RPL27A, RPLP1, IL6ST, PIK3CB, PLCG1, PRKCA | More | | Flibanserin | hsa05200 | Pathways in cancer | 8.39E-06 | 22 | Q13751, P42338, P08238, P42224, P25963, P19174, P17252, P43246, P10826, P14923, Q13489, P49767, P14921, P31751, P62873, P50151, P78417, O75293, P0DP23, P01568, P14784, P40189 | LAMB3, PIK3CB, HSP90AB1, STAT1, NFKBIA, PLCG1, PRKCA, MSH2, RARB, JUP, BIRC3, VEGFC, ETS1, AKT2, GNB1, GNG10, GSTO1, GADD45B, CALM1, IFNA21, IL2RB, IL6ST | More | | Flibanserin | hsa05202 | Transcriptional misregulation in cancer | 1.07E-05 | 16 | Q12778, Q15532, Q13315, P14780, P14923, Q15744, Q16548, Q13489, Q13077, O15550, P35226, P05164, P12838, P08246, Q9C0K0, P24522 | FOXO1, SS18, ATM, MMP9, JUP, CEBPE, BCL2A1, BIRC3, TRAF1, UTX, BMI1, MPO, DEFA4, ELA2, BCL11B, GADD45A | More | | Flibanserin | hsa05203 | Viral carcinogenesis | 6.35E-03 | 7 | P30281, Q15283, P06396, P01889, P10321, P62807, O60814 | CCND3, RASA2, GSN, HLA-B, HLA-C, HIST1H2BC, H2BC12 | More | | Flibanserin | hsa05204 | Chemical carcinogenesis | 1.09E-03 | 3 | P09211, P78417, P11712 | GSTP1, GSTO1, CYP2C9 | More | | Flibanserin | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | Flibanserin | hsa05206 | MicroRNAs in cancer | 2.97E-03 | 6 | P15311, P21860, P61978, P46531, P63279, P22105 | VIL2, ERBB3, HNRPK, NOTCH1, UBE2I, TNXB | More | | Flibanserin | hsa05211 | Renal cell carcinoma | 2.02E-03 | 2 | Q13153, P31751 | PAK1, AKT2 | More | | Flibanserin | hsa05212 | Pancreatic cancer | 4.78E-02 | 1 | P31751 | AKT2 | More | | Flibanserin | hsa05213 | Endometrial cancer | 4.72E-03 | 3 | O15169, P31751, Q02750 | AXIN1, AKT2, MAP2K1 | More | | Flibanserin | hsa05214 | Glioma | 6.17E-05 | 6 | P0DP23, P17252, P42338, P31751, P19174, O75293 | CALM1, PRKCA, PIK3CB, AKT2, PLCG1, GADD45B | More | | Flibanserin | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | | Flibanserin | hsa05218 | Melanoma | 3.01E-02 | 1 | P31751 | AKT2 | More | | Flibanserin | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | Flibanserin | hsa05220 | Chronic myeloid leukemia | 4.19E-02 | 1 | P31751 | AKT2 | More | | Flibanserin | hsa05221 | Acute myeloid leukemia | 4.19E-02 | 1 | P31751 | AKT2 | More | | Flibanserin | hsa05222 | Small cell lung cancer | 1.36E-04 | 11 | P10826, P31751, P42338, Q13751, Q13489, P10415, P25963, Q13077, O00463, P24522, O75293 | RARB, AKT2, PIK3CB, LAMB3, BIRC3, BCL2, NFKBIA, TRAF1, TRAF5, GADD45A, GADD45B | More | | Flibanserin | hsa05223 | Non-small cell lung cancer | 1.14E-05 | 7 | P17252, P31751, P42338, P19174, P10826, Q9HC35, O75293 | PRKCA, AKT2, PIK3CB, PLCG1, RARB, EML4, GADD45B | More | | Flibanserin | hsa05224 | Breast cancer | 4.75E-02 | 4 | P49841, Q92837, P04637, P24522 | GSK3B, FRAT1, TP53, GADD45A | More | | Flibanserin | hsa05226 | Gastric cancer | 4.72E-03 | 3 | Q02750, P31751, O15169 | MAP2K1, AKT2, AXIN1 | More | | Flibanserin | hsa05230 | Central carbon metabolism in cancer | 4.78E-02 | 1 | P31751 | AKT2 | More | | Flibanserin | hsa05231 | Choline metabolism in cancer | 4.91E-03 | 5 | P42338, Q9Y259, P19174, P23743, P17252 | PIK3CB, CHKB, PLCG1, DGKA, PRKCA | More | | Flibanserin | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 3.61E-05 | 10 | O95267, P07766, P20963, P09693, P06239, O60603, Q04759, Q16539, Q9HC35, P01730 | RASGRP1, CD3E, CD247, CD3G, LCK, TLR2, PRKCQ, MAPK14, EML4, CD4 | More | | Flibanserin | hsa05310 | Asthma | 3.88E-02 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Flibanserin | hsa05321 | Inflammatory bowel disease | 4.75E-05 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, Q9HBE5 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL21R | More | | Flibanserin | hsa05322 | Systemic lupus erythematosus | 1.11E-05 | 14 | P08246, P08311, P09871, P01375, P10747, P13765, Q6FI13, Q93077, P62807, Q16778, O60814, P68431, P12814, P05455 | ELA2, CTSG, C1S, TNF, CD28, HLA-DOB, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, ACTN1, SSB | More | | Flibanserin | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Flibanserin | hsa05332 | Graft-versus-host disease | 6.57E-07 | 6 | P13765, P48023, P10747, P01375, P26715, Q13241 | HLA-DOB, FASLG, CD28, TNF, KLRC1, KLRD1 | More | | Flibanserin | hsa05340 | Primary immunodeficiency | 1.28E-03 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | | Flibanserin | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.48E-02 | 1 | P54284 | CACNB3 | More | | Flibanserin | hsa05414 | Dilated cardiomyopathy | 4.55E-02 | 2 | P54284, P26678 | CACNB3, PLN | More | | Flibanserin | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | | Flibanserin | hsa05418 | Fluid shear stress and atherosclerosis | 1.27E-05 | 10 | Q16539, P31751, Q14145, P10599, P14780, P01375, P04637, P14778, P27930, P0DP23 | MAPK14, AKT2, KEAP1, TXN, MMP9, TNF, TP53, IL1R1, IL1R2, CALM1 | More | | |